Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PEDMARK safely and effectively. See full prescribing information for PEDMARK. PEDMARK® (sodium thiosulfate injection), for intravenous use Initial U.S. Approval: 1992
Medication labelWhy this: Advisory · dailymed-prescription
PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.
- generic_name
- sodium thiosulfate
- product_names
- SODIUM THIOSULFATE
- ndc
- 73077-010, 73077-010-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en